(Q78271812)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30987166%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

scholarly article

1 reference

inferred from PubMed Central ID database lookup

title

Modelling of Protein Kinase Signaling Pathways in Melanoma and Other Cancers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30987166%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

author name string

Manfred Kunz

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30987166%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

Julio Vera

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30987166%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

publication date

3 April 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30987166%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30987166%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30987166%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30987166%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

13 December 2019

copyright license

start time

3 April 2019

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Essential role for oncogenic Ras in tumour maintenance

1 reference

12 December 2020

Genomic analysis of metastasis reveals an essential role for RhoC

1 reference

12 December 2020

Molecular classification of cutaneous malignant melanoma by gene expression profiling

1 reference

12 December 2020

Mutations of the BRAF gene in human cancer

1 reference

12 December 2020

Distinct sets of genetic alterations in melanoma

1 reference

12 December 2020

Cyclin-dependent kinase 2 expression in human melanomas and benign melanocytic skin lesions.

1 reference

12 December 2020

Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues

1 reference

12 December 2020

A systems biological approach suggests that transcriptional feedback regulation by dual-specificity phosphatase 6 shapes extracellular signal-related kinase activity in RAS-transformed fibroblasts

1 reference

12 December 2020

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma

1 reference

12 December 2020

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

1 reference

12 December 2020

E2F1 in melanoma progression and metastasis

1 reference

12 December 2020

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

1 reference

12 December 2020

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

1 reference

12 December 2020

Investigating dynamics of inhibitory and feedback loops in ERK signalling using power-law models

1 reference

12 December 2020

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

12 December 2020

Identification of new genes associated with melanoma.

1 reference

12 December 2020

Exome sequencing identifies GRIN2A as frequently mutated in melanoma

1 reference

12 December 2020

Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling

1 reference

12 December 2020

Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma.

1 reference

12 December 2020

Targeting protein prenylation for cancer therapy

1 reference

12 December 2020

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

1 reference

12 December 2020

Therapeutic implications of KIT in melanoma

1 reference

12 December 2020

Melanoma genome sequencing reveals frequent PREX2 mutations

1 reference

12 December 2020

A landscape of driver mutations in melanoma

1 reference

12 December 2020

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

1 reference

12 December 2020

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

1 reference

12 December 2020

Mutations in ERBB4 may have a minor role in melanoma pathogenesis

1 reference

12 December 2020

TERT promoter mutations in familial and sporadic melanoma

1 reference

12 December 2020

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

1 reference

12 December 2020

Kinetic modeling-based detection of genetic signatures that provide chemoresistance via the E2F1-p73/DNp73-miR-205 network

1 reference

12 December 2020

Network quantification of EGFR signaling unveils potential for targeted combination therapy.

1 reference

12 December 2020

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

1 reference

12 December 2020

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

1 reference

12 December 2020

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

1 reference

12 December 2020

Discovery and saturation analysis of cancer genes across 21 tumour types

1 reference

12 December 2020

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

1 reference

12 December 2020

1 reference

12 December 2020

A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors

1 reference

12 December 2020

Phosphoproteomics of MAPK inhibition in BRAF-mutated cells and a role for the lethal synergism of dual BRAF and CK2 inhibition.

1 reference

12 December 2020

SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer

1 reference

12 December 2020

Nras in melanoma: targeting the undruggable target

1 reference

12 December 2020

ERBB3 is required for metastasis formation of melanoma cells

1 reference

12 December 2020

The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα

1 reference

12 December 2020

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

1 reference

12 December 2020

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction

1 reference

12 December 2020

Therapy-induced tumour secretomes promote resistance and tumour progression

1 reference

12 December 2020

New strategies in melanoma: entering the era of combinatorial therapy

1 reference

12 December 2020

Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway

1 reference

12 December 2020

Intra- and Inter-Tumoral Homogeneity of BRAF(V600E) Mutations in Melanoma Tumors.

1 reference

12 December 2020

Genomic Classification of Cutaneous Melanoma

1 reference

12 December 2020

CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.

1 reference

12 December 2020

Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells

1 reference

12 December 2020

Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

1 reference

12 December 2020

MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment

1 reference

12 December 2020

The Genetic Evolution of Melanoma from Precursor Lesions

1 reference

12 December 2020

The genomic landscape of cutaneous melanoma

1 reference

12 December 2020

Inflammation-Induced Plasticity in Melanoma Therapy and Metastasis

1 reference

12 December 2020

The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer

1 reference

12 December 2020

Protease-Activated Receptors and other G-Protein-Coupled Receptors: the Melanoma Connection

1 reference

12 December 2020

MAPK kinase signalling dynamics regulate cell fate decisions and drug resistance

1 reference

12 December 2020

Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance.

1 reference

12 December 2020

Mapping heterogeneity in patient-derived melanoma cultures by single-cell RNA-seq

1 reference

12 December 2020

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).

1 reference

12 December 2020

Targeted agents and immunotherapies: optimizing outcomes in melanoma

1 reference

12 December 2020

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

1 reference

12 December 2020

Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model

1 reference

12 December 2020

Unraveling a tumor type-specific regulatory core underlying E2F1-mediated epithelial-mesenchymal transition to predict receptor protein signatures

1 reference

12 December 2020

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.

1 reference

12 December 2020

PD-L1 inhibitors in the pipeline: Promise and progress.

1 reference

12 December 2020

A web platform for the network analysis of highthroughput data in melanoma and its use to investigate mechanisms of resistance to anti-PD1 immunotherapy.

1 reference

12 December 2020

MiR-205-5p and miR-342-3p cooperate in the repression of the E2F1 transcription factor in the context of anticancer chemotherapy resistance.

1 reference

12 December 2020

Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: An integrated approach to understanding targeted therapy.

1 reference

12 December 2020

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma.

1 reference

12 December 2020

The promise and challenges of immune agonist antibody development in cancer

1 reference

12 December 2020

Patterns of genomic evolution in advanced melanoma.

1 reference

12 December 2020

RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas

1 reference

12 December 2020

Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling

1 reference

12 December 2020

Rates of ERBB2 Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-Amplified Acral Melanoma

1 reference

12 December 2020

1 reference

12 December 2020

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

1 reference

12 December 2020

Receptor Tyrosine Kinase-Targeted Cancer Therapy

1 reference

12 December 2020

Identifiers

DOI

10.3390/CANCERS11040465

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30987166%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30987166%20AND%20SRC:MED&resulttype=core&format=json

13 December 2019

1 reference